Fig. 5From: Targeting autophagy potentiates the anti-tumor effect of PARP inhibitor in pediatric chronic myeloid leukemiaAutophagy inhibition potentiated the cytotoxicity of talazoparib in CML cells. CML P#1 cells (a) and P#2 (b) were treated with 20 μM of talazoparib in with/without of 20 μM of chloroquine. The expression of LC3-I/II was detected by immunoblot analysis. Cell viability was measured by CCK-8 assay (N = 3, mean ± SD, **P < 0.01)Back to article page